{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:52:43Z","timestamp":1776336763819,"version":"3.51.2"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11632-1","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:22:43Z","timestamp":1776331363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epithelial-mesenchymal transition and its role in drug resistance of cervical cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4226-1994","authenticated-orcid":false,"given":"Parisa","family":"Cheraghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9231-889X","authenticated-orcid":false,"given":"Mohammad","family":"Khalaj-Kondori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-599X","authenticated-orcid":false,"given":"Amin","family":"Moqadami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"2","key":"11632_CR1","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B et al (2023) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. The Lancet Global Health 11(2):e197\u2013e206","journal-title":"The Lancet Global Health"},{"issue":"1","key":"11632_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"key":"11632_CR3","unstructured":"https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/zervixkarzinom\/"},{"issue":"5","key":"11632_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/medicina59050925","volume":"59","author":"M Schubert","year":"2023","unstructured":"Schubert M, Bauerschlag DO, Muallem MZ, Maass N, Alkatout I (2023) Challenges in the diagnosis and individualized treatment of cervical cancer. Medicina (Kaunas) 59(5):925","journal-title":"Medicina (Kaunas)"},{"key":"11632_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155136","author":"G Srinivasan","year":"2024","unstructured":"Srinivasan G (2024) Cervical cancer: novel treatment strategies offer renewed optimism. Pathology. https:\/\/doi.org\/10.1016\/j.prp.2024.155136","journal-title":"Pathology"},{"key":"11632_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2019.02.009","volume":"137","author":"M Liontos","year":"2019","unstructured":"Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos M-A, Bamias A (2019) Systemic therapy in cervical cancer: 30 years in review. Crit Rev Oncol-Hematol 137:9\u201317","journal-title":"Crit Rev Oncol-Hematol"},{"key":"11632_CR7","doi-asserted-by":"crossref","unstructured":"Dlamini Z, Khanyile R, Molefi T, Damane BP, Hull R, Mehrotra R (2024) Chapter 10 - Conclusion: Overcoming chemoresistance in cervical cancer. In: Dlamini Z (ed) Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer 21:179\u2013183","DOI":"10.1016\/B978-0-443-28985-9.00003-3"},{"key":"11632_CR8","doi-asserted-by":"crossref","unstructured":"Marima R, Mosoane B, Mtshali N, Basera A, Kgatle M, Grech G et al (2024) Chapter 4 - Mechanisms of chemotherapy resistance in cervical cancer. In: Dlamini Z (ed) Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer 21:53\u201370","DOI":"10.1016\/B978-0-443-28985-9.00012-4"},{"key":"11632_CR9","volume":"6","author":"IA George","year":"2022","unstructured":"George IA, Chauhan R, Dhawale RE, Iyer R, Limaye S, Sankaranarayanan R et al (2022) Insights into therapy resistance in cervical cancer. Advances in Cancer Biology 6:100074","journal-title":"Advances in Cancer Biology"},{"issue":"1","key":"11632_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54177-z","volume":"9","author":"L Jing","year":"2019","unstructured":"Jing L, Bo W, Yourong F, Tian W, Shixuan W, Mingfu W (2019) Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells. Sci Rep 9(1):17727","journal-title":"Sci Rep"},{"issue":"5","key":"11632_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ddr.21942","volume":"83","author":"M Wu","year":"2022","unstructured":"Wu M, Chen G, Liao X, Xiao L, Zheng J (2022) YTHDF2 interference suppresses the EMT of cervical cancer cells and enhances cisplatin chemosensitivity by regulating AXIN1. Drug Dev Res 83(5):1190\u20131200","journal-title":"Drug Dev Res"},{"key":"11632_CR12","unstructured":"Wu S, Jin P, Wang D, Wang C, Xu T (2024) The relationship between microRNAs and EMT process in cervical cancer. Cancer Females 1"},{"issue":"2","key":"11632_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.canlet.2014.09.021","volume":"356","author":"R Qureshi","year":"2015","unstructured":"Qureshi R, Arora H, Rizvi M (2015) EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett 356(2):321\u2013331","journal-title":"Cancer Lett"},{"issue":"S1","key":"11632_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ijgo.13865","volume":"155","author":"N Bhatla","year":"2021","unstructured":"Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2021) Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet 155(S1):28\u201344","journal-title":"Int J Gynaecol Obstet"},{"key":"11632_CR15","first-page":"1","volume":"90","author":"W Iarc","year":"2007","unstructured":"Iarc W (2007) Human papillomaviruses: IARC monographs on the evaluation of carcinogenic risks to humans. IARC Monogr Eval Carcinog Risks Hum 90:1\u2013636","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"issue":"7","key":"11632_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1083\/jcb.200601018","volume":"172","author":"JM Lee","year":"2006","unstructured":"Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial\u2013mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172(7):973\u2013981","journal-title":"J Cell Biol"},{"issue":"14","key":"11632_CR17","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1158\/0008-5472.CAN-05-0616","volume":"65","author":"EW Thompson","year":"2005","unstructured":"Thompson EW, Newgreen DF (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65(14):5991\u20135995","journal-title":"Cancer Res"},{"issue":"20","key":"11632_CR18","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1016\/j.cell.2025.08.033","volume":"188","author":"CX Zhang","year":"2025","unstructured":"Zhang CX, Huang RY-J, Sheng G, Thiery JP (2025) Epithelial-mesenchymal transition. Cell 188(20):5436\u20135486","journal-title":"Cell"},{"issue":"2","key":"11632_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0975-8844.106190","volume":"4","author":"SB Ghanta","year":"2012","unstructured":"Ghanta SB, Nayan N, Kumar NGR, Pasupuleti S (2012) Epithelial-mesenchymal transition: understanding the basic concept. J Orofac Sci 4(2):82\u201386","journal-title":"J Orofac Sci"},{"issue":"5","key":"11632_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/ecco-jcc\/jjy201","volume":"13","author":"S Lovisa","year":"2019","unstructured":"Lovisa S, Genovese G, Danese S (2019) Role of epithelial-to-mesenchymal transition in inflammatory bowel disease. J Crohns Colitis 13(5):659\u2013668","journal-title":"J Crohns Colitis"},{"issue":"6","key":"11632_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T (2020) Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol 13(6):100773","journal-title":"Transl Oncol"},{"issue":"3","key":"11632_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1515\/oncologie-2023-0562","volume":"26","author":"J Chen","year":"2024","unstructured":"Chen J, Yang T, Xiao T, Wang Z, He F, Bao T-t et al (2024) Overview and new insights of lysine-specific histone demethylase 1 in colorectal cancer: promoting epithelial-mesenchymal transition and stemness features of cancer stem cells. Oncologie 26(3):369\u201377","journal-title":"Oncologie"},{"issue":"12","key":"11632_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01801-0","volume":"39","author":"K Mortezaee","year":"2022","unstructured":"Mortezaee K, Majidpoor J, Kharazinejad E (2022) Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol 39(12):193","journal-title":"Med Oncol"},{"issue":"14","key":"11632_CR24","doi-asserted-by":"publisher","first-page":"11386","DOI":"10.3390\/ijms241411386","volume":"24","author":"G Manfioletti","year":"2023","unstructured":"Manfioletti G, Fedele M (2023) Epithelial\u2013mesenchymal transition (EMT). Int J Mol Sci 24(14):11386","journal-title":"Int J Mol Sci"},{"issue":"6","key":"11632_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M et al (2020) Guidelines and definitions for research on epithelial\u2013mesenchymal transition. Nat Rev Mol Cell Biol 21(6):341\u201352","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"11632_CR26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704\u201315","journal-title":"Cell"},{"issue":"4","key":"11632_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189358","volume":"1880","author":"Y-M Chen","year":"2025","unstructured":"Chen Y-M, Chen L, Xu Y-X, Cheng H-B, Zhou J-L (2025) Shared mechanisms for metastasis and drug resistance in prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1880(4):189358","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"1","key":"11632_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, Fatima K, Aisha S, Malik F (2024) Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal 22(1):109","journal-title":"Cell Commun Signal"},{"issue":"7","key":"11632_CR29","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","volume":"95","author":"J De Las Rivas","year":"2021","unstructured":"De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A (2021) Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol 95(7):2279\u20132297","journal-title":"Arch Toxicol"},{"issue":"02","key":"11632_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cpt.2024.07.002","volume":"03","author":"R Bangarh","year":"2025","unstructured":"Bangarh R, Saini RV, Saini AK, Singh T, Joshi H, Ramniwas S et al (2025) Dynamics of epithelial-mesenchymal plasticity driving cancer drug resistance. Cancer Pathogenesis Therapy 03(02):120\u2013128","journal-title":"Cancer Pathogenesis Therapy"},{"issue":"1","key":"11632_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10555-023-10162-7","volume":"43","author":"N Ebrahimi","year":"2024","unstructured":"Ebrahimi N, Manavi MS, Faghihkhorasani F, Fakhr SS, Baei FJ, Khorasani FF et al (2024) Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response. Cancer Metastasis Rev 43(1):457\u2013479","journal-title":"Cancer Metastasis Rev"},{"key":"11632_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637675","volume":"9","author":"Y Ni","year":"2021","unstructured":"Ni Y, Zhou X, Yang J, Shi H, Li H, Zhao X et al (2021) The role of tumor-stroma interactions in drug resistance within tumor microenvironment. Front Cell Dev Biol 9:637675","journal-title":"Front Cell Dev Biol"},{"key":"11632_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-01771-9","volume":"21","author":"Y Qi","year":"2021","unstructured":"Qi Y, Yang W, Liu S, Han F, Wang H, Zhao Y et al (2021) Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT. Cancer Cell Int 21:1\u201311","journal-title":"Cancer Cell Int"},{"key":"11632_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.115942","volume":"232","author":"HM Saleem","year":"2023","unstructured":"Saleem HM, Ramaiah P, Gupta J, Jalil AT, Kadhim NA, Alsaikhan F et al (2023) Nanotechnology-empowered lung cancer therapy: from EMT role in cancer metastasis to application of nanoengineered structures for modulating growth and metastasis. Environ Res 232:115942","journal-title":"Environ Res"},{"issue":"1","key":"11632_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04191-w","volume":"7","author":"H Hiramoto","year":"2017","unstructured":"Hiramoto H, Muramatsu T, Ichikawa D, Tanimoto K, Yasukawa S, Otsuji E et al (2017) miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Sci Rep 7(1):4002","journal-title":"Sci Rep"},{"issue":"4\u20135","key":"11632_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drup.2008.07.001","volume":"11","author":"M Sabbah","year":"2008","unstructured":"Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A et al (2008) Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11(4\u20135):123\u2013151","journal-title":"Drug Resist Updat"},{"issue":"1","key":"11632_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY-J, Jackson RA, Thiery JP (2016) EMT: 2016. Cell 166(1):21\u201345","journal-title":"Cell"},{"issue":"11","key":"11632_CR38","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/nm.3336","volume":"19","author":"WL Tam","year":"2013","unstructured":"Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19(11):1438\u20131449","journal-title":"Nat Med"},{"issue":"1","key":"11632_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12195-021-00694-9","volume":"15","author":"B Buyuk","year":"2022","unstructured":"Buyuk B, Jin S, Ye K (2022) Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis. Cell Mol Bioeng 15(1):1\u201313","journal-title":"Cell Mol Bioeng"},{"issue":"4","key":"11632_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4252\/wjsc.v5.i4.188","volume":"5","author":"M Garg","year":"2013","unstructured":"Garg M (2013) Epithelial-mesenchymal transition - activating transcription factors - multifunctional regulators in cancer. World J Stem Cells 5(4):188\u2013195","journal-title":"World J Stem Cells"},{"key":"11632_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5040041","author":"J Zhang","year":"2016","unstructured":"Zhang J, Tian XJ, Xing J (2016) Signal transduction pathways of EMT induced by TGF-\u03b2, SHH, and WNT and their crosstalks. J Clin Med. https:\/\/doi.org\/10.3390\/jcm5040041","journal-title":"J Clin Med"},{"issue":"19","key":"11632_CR42","first-page":"5190","volume":"52","author":"CL Sommers","year":"1992","unstructured":"Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW et al (1992) Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 52(19):5190\u20135197","journal-title":"Cancer Res"},{"issue":"1","key":"11632_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-91","volume":"12","author":"AM Haslehurst","year":"2012","unstructured":"Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J et al (2012) EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12(1):91","journal-title":"BMC Cancer"},{"issue":"1","key":"11632_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep20502","volume":"6","author":"D Huang","year":"2016","unstructured":"Huang D, Duan H, Huang H, Tong X, Han Y, Ru G et al (2016) Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep 6(1):20502","journal-title":"Sci Rep"},{"issue":"10","key":"11632_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109299","volume":"9","author":"Y Shen","year":"2014","unstructured":"Shen Y, Zhou J, Li Y, Ye F, Wan X, Lu W et al (2014) MiR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PLOS ONE 9(10):e109299","journal-title":"PLOS ONE"},{"issue":"1","key":"11632_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101711","volume":"13","author":"P Xia","year":"2025","unstructured":"Xia P (2025) The significance of epithelial-mesenchymal transition (EMT) in the initiation, plasticity, and treatment of glioblastoma. Genes Dis 13(1):101711","journal-title":"Genes Dis"},{"issue":"7579","key":"11632_CR47","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST et al (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579):472\u20136","journal-title":"Nature"},{"issue":"3","key":"11632_CR48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cpt.2024.07.001","volume":"3","author":"MCP Dela Cruz","year":"2025","unstructured":"Dela Cruz MCP, Medina PMB (2025) Epithelial\u2013mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC). Cancer Pathog Ther 3(3):215\u2013225","journal-title":"Cancer Pathog Ther"},{"issue":"1","key":"11632_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX et al (2023) Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther 8(1):113","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"11632_CR50","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jhep.2010.12.043","volume":"55","author":"X Chen","year":"2011","unstructured":"Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J (2011) Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 55(4):838\u2013845","journal-title":"J Hepatol"},{"key":"11632_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau8544","author":"Y Katsuno","year":"2019","unstructured":"Katsuno Y, Meyer DS, Zhang Z, Shokat KM, Akhurst RJ, Miyazono K et al (2019) Chronic TGF-\u03b2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aau8544","journal-title":"Sci Signal"},{"issue":"1","key":"11632_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R (2024) Wnt\/beta-catenin-driven EMT regulation in human cancers. Cell Mol Life Sci 81(1):79","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"11632_CR53","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3892\/ijo.2016.3342","volume":"48","author":"JJ Deng","year":"2016","unstructured":"Deng JJ, Zhang W, Xu XM, Zhang F, Tao WP, Ye JJ et al (2016) Twist mediates an aggressive phenotype in human colorectal cancer cells. Int J Oncol 48(3):1117\u201324","journal-title":"Int J Oncol"},{"key":"11632_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-91","volume":"12","author":"AM Haslehurst","year":"2012","unstructured":"Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J et al (2012) EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12:91","journal-title":"BMC Cancer"},{"issue":"8","key":"11632_CR55","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/emmm.201302827","volume":"5","author":"FA Siebzehnrubl","year":"2013","unstructured":"Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR et al (2013) The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 5(8):1196\u20131212","journal-title":"EMBO Mol Med"},{"issue":"16","key":"11632_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168972","volume":"25","author":"P Tomecka","year":"2024","unstructured":"Tomecka P, Kunachowicz D, G\u00f3rczy\u0144ska J, Gebuza M, Ku\u017anicki J, Skinderowicz K et al (2024) Factors determining epithelial-mesenchymal transition in cancer progression. Int J Mol Sci 25(16):8972","journal-title":"Int J Mol Sci"},{"issue":"7","key":"11632_CR57","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/medicina59071229","volume":"59","author":"IG Dicu-Andreescu","year":"2023","unstructured":"Dicu-Andreescu IG, Marinca\u0219 AM, Ungureanu VG, Ionescu SO, Prunoiu VM, Br\u0103tucu E (2023) Current therapeutic approaches in cervical cancer based on the stage of the disease: is there room for improvement? Medicina (Kaunas) 59(7):1229","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"11632_CR58","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ijrobp.2020.11.052","volume":"109","author":"C Federico","year":"2021","unstructured":"Federico C, Sun J, Muz B, Alhallak K, Cosper PF, Muhammad N et al (2021) Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side effect profile. Int J Radiat Oncol Biol Phys 109(5):1483\u20131494","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11632_CR59","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DDDT.S106412","volume":"10","author":"H Zhu","year":"2016","unstructured":"Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X (2016) Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther 10:1885\u20131895","journal-title":"Drug Des Devel Ther"},{"key":"11632_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1055356","volume":"9","author":"A Schoeberl","year":"2022","unstructured":"Schoeberl A, Gutmann M, Theiner S, Corte-Rodr\u00edguez M, Braun G, Vician P et al (2022) The copper transporter CTR1 and cisplatin accumulation at the single-cell level by LA-ICP-TOFMS. Front Mol Biosci 9:1055356","journal-title":"Front Mol Biosci"},{"key":"11632_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.145000","volume":"759","author":"Z Chen","year":"2020","unstructured":"Chen Z, Ling K, Zhu Y, Deng L, Li Y, Liang Z (2020) Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters. Gene 759:145000","journal-title":"Gene"},{"issue":"3","key":"11632_CR62","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.7314\/APJCP.2014.15.3.1403","volume":"15","author":"M Roy","year":"2014","unstructured":"Roy M, Mukherjee S (2014) Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac J Cancer Prev 15(3):1403\u20131410","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"11632_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bcp.2004.03.022","volume":"68","author":"GL Beretta","year":"2004","unstructured":"Beretta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F et al (2004) Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 68(2):283\u2013291","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"11632_CR64","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bcp.2006.10.003","volume":"73","author":"J Zisowsky","year":"2007","unstructured":"Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M et al (2007) Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 73(2):298\u2013307","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"11632_CR65","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jps.22752","volume":"101","author":"Q Li","year":"2012","unstructured":"Li Q, Peng X, Yang H, Rodriguez JA, Shu Y (2012) Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells. J Pharm Sci 101(1):394\u2013404","journal-title":"J Pharm Sci"},{"issue":"43","key":"11632_CR66","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1038\/onc.2010.303","volume":"29","author":"L Li","year":"2010","unstructured":"Li L, Wei XH, Pan YP, Li HC, Yang H, He QH et al (2010) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K\/AKT signaling. Oncogene 29(43):5785\u20135795","journal-title":"Oncogene"},{"issue":"1","key":"11632_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3032590","volume":"2022","author":"Y Hou","year":"2022","unstructured":"Hou Y, Dong Z, Zhong W, Yin L, Li X, Kuerban G et al (2022) FOXM1 promotes drug resistance in cervical cancer cells by regulating ABCC5 gene transcription. BioMed Res Int 2022(1):3032590","journal-title":"BioMed Res Int"},{"key":"11632_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100905","volume":"66","author":"J Fan","year":"2023","unstructured":"Fan J, To KKW, Chen Z-S, Fu L (2023) ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance. Drug Resist Updat 66:100905","journal-title":"Drug Resist Updat"},{"key":"11632_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2022.100074","author":"IA George","year":"2022","unstructured":"George IA, Chauhan R, Dhawale RE, Iyer R, Limaye S, Sankaranarayanan R et al (2022) Insights into therapy resistance in cervical cancer. Advances in Cancer Biology - Metastasis. https:\/\/doi.org\/10.1016\/j.adcanc.2022.100074","journal-title":"Advances in Cancer Biology - Metastasis"},{"issue":"1","key":"11632_CR70","first-page":"1","volume":"4","author":"MY Lee","year":"2012","unstructured":"Lee MY, Shen MR (2012) Epithelial-mesenchymal transition in cervical carcinoma. Am J Transl Res 4(1):1\u201313","journal-title":"Am J Transl Res"},{"issue":"1","key":"11632_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01957-4","volume":"22","author":"M Liaghat","year":"2024","unstructured":"Liaghat M, Ferdousmakan S, Mortazavi SH, Yahyazadeh S, Irani A, Banihashemi S et al (2024) The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal 22(1):575","journal-title":"Cell Commun Signal"},{"issue":"1","key":"11632_CR72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41698-021-00200-4","volume":"5","author":"G Wang","year":"2021","unstructured":"Wang G, Xu D, Zhang Z, Li X, Shi J, Sun J et al (2021) The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. NPJ Precis Oncol 5(1):56","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"11632_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274607","volume":"17","author":"BI Abas","year":"2022","unstructured":"Abas BI, Demirbolat GM, Cevik O (2022) Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel. PLoS One 17(9):e0274607","journal-title":"PLoS One"},{"issue":"1S","key":"11632_CR74","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/MD.0000000000004764","volume":"95","author":"JN Rich","year":"2016","unstructured":"Rich JN (2016) Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine 95(1S):S2\u2013S7","journal-title":"Medicine"},{"key":"11632_CR75","doi-asserted-by":"publisher","first-page":"1417201","DOI":"10.3389\/fimmu.2024.1417201","volume":"15","author":"Z-N Lei","year":"2024","unstructured":"Lei Z-N, Teng Q-X, Koya J, Liu Y, Chen Z, Zeng L et al (2024) The correlation between cancer stem cells and epithelial-mesenchymal transition: Molecular mechanisms and significance in cancer theragnosis. Front Immunol 15:1417201","journal-title":"Front Immunol"},{"issue":"3","key":"11632_CR76","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3892\/or.2025.8942","volume":"54","author":"Y-F Li","year":"2025","unstructured":"Li Y-F, Su S, Luo Y, Wei C, He J, Song L-D et al (2025) Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer. Oncol Rep 54(3):109","journal-title":"Oncol Rep"},{"issue":"34","key":"11632_CR77","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34):4741\u20134751","journal-title":"Oncogene"},{"issue":"5","key":"11632_CR78","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871\u2013890","journal-title":"Cell"},{"issue":"1","key":"11632_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0012-z","volume":"3","author":"GM Wahl","year":"2017","unstructured":"Wahl GM, Spike BT (2017) Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. NPJ Breast Cancer 3(1):14","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"11632_CR80","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983\u20133988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"11632_CR81","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/stem.3157","volume":"38","author":"Y He","year":"2020","unstructured":"He Y, Xiao M, Fu H, Chen L, Qi L, Liu D et al (2020) cPLA2\u03b1 reversibly regulates different subsets of cancer stem cells transformation in cervical cancer. Stem Cells 38(4):487\u2013503","journal-title":"Stem Cells"},{"issue":"10","key":"11632_CR82","doi-asserted-by":"publisher","first-page":"13059","DOI":"10.1007\/s13277-016-5294-5","volume":"37","author":"P Ranji","year":"2016","unstructured":"Ranji P, Salmani Kesejini T, Saeedikhoo S, Alizadeh AM (2016) Targeting cancer stem cell-specific markers and\/or associated signaling pathways for overcoming cancer drug resistance. Tumor Biol 37(10):13059\u201313075","journal-title":"Tumor Biol"},{"issue":"2","key":"11632_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1144","volume":"2","author":"N Sudhalkar","year":"2019","unstructured":"Sudhalkar N, Rathod NP, Mathews A, Chopra S, Sriram H, Shrivastava SK et al (2019) Potential role of cancer stem cells as biomarkers and therapeutic targets in cervical cancer. Cancer Reports 2(2):e1144","journal-title":"Cancer Reports"},{"issue":"1","key":"11632_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00206-5","volume":"10","author":"B Dong","year":"2021","unstructured":"Dong B, Li S, Zhu S, Yi M, Luo S, Wu K (2021) MiRNA-mediated EMT and CSCs in cancer chemoresistance. Exp Hematol Oncol 10(1):12","journal-title":"Exp Hematol Oncol"},{"key":"11632_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O'Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 9:402","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"11632_CR86","doi-asserted-by":"publisher","first-page":"BSR20211754","DOI":"10.1042\/BSR20211754","volume":"42","author":"P Debnath","year":"2022","unstructured":"Debnath P, Huirem RS, Dutta P, Palchaudhuri S (2022) Epithelial\u2013mesenchymal transition and its transcription factors. Biosci Rep 42(1):BSR20211754","journal-title":"Biosci Rep"},{"issue":"3","key":"11632_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e41964","volume":"11","author":"ANKV Sravani","year":"2025","unstructured":"Sravani ANKV, Thomas J (2025) Targeting epithelial-mesenchymal transition signaling pathways with dietary phytocompounds and repurposed drug combinations for overcoming drug resistance in various cancers. Heliyon 11(3):e41964","journal-title":"Heliyon"},{"key":"11632_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095167","author":"R Di Fiore","year":"2022","unstructured":"Di Fiore R, Suleiman S, Drago-Ferrante R, Subbannayya Y, Pentimalli F, Giordano A et al (2022) Cancer stem cells and their possible implications in cervical cancer: a short review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23095167","journal-title":"Int J Mol Sci"},{"key":"11632_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101276","volume":"83","author":"M Jiang","year":"2025","unstructured":"Jiang M, Wang J, Li Y, Zhang K, Wang T, Bo Z et al (2025) EMT and cancer stem cells: drivers of therapy resistance and promising therapeutic targets. Drug Resist Updat 83:101276","journal-title":"Drug Resist Updat"},{"key":"11632_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672222","author":"X Liu","year":"2021","unstructured":"Liu X, He M, Li L, Wang X, Han S, Zhao J et al (2021) EMT and cancer cell stemness associated with chemotherapeutic resistance in esophageal cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.672222","journal-title":"Front Oncol"},{"key":"11632_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098063","author":"A Popiel-Kopaczyk","year":"2023","unstructured":"Popiel-Kopaczyk A, Piotrowska A, Sputa-Grzegrzolka P, Smolarz B, Romanowicz H, Dziegiel P et al (2023) The immunohistochemical expression of epithelial-mesenchymal transition markers in precancerous lesions and cervical cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24098063","journal-title":"Int J Mol Sci"},{"issue":"21","key":"11632_CR92","doi-asserted-by":"publisher","first-page":"35351","DOI":"10.18632\/oncotarget.10169","volume":"8","author":"R Huang","year":"2017","unstructured":"Huang R, Rofstad EK (2017) Cancer stem cells (CSCs), cervical CSCs and targeted therapies. Oncotarget 8(21):35351\u201335367","journal-title":"Oncotarget"},{"issue":"13","key":"11632_CR93","doi-asserted-by":"publisher","first-page":"10697","DOI":"10.18632\/oncotarget.4037","volume":"6","author":"A Mitra","year":"2015","unstructured":"Mitra A, Mishra L, Li S (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6(13):10697\u2013711","journal-title":"Oncotarget"},{"issue":"1","key":"11632_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-022-00540-2","volume":"28","author":"J Ma","year":"2022","unstructured":"Ma J, Ye W, Yang Y, Wu T, Wang Y, Li J et al (2022) The interaction between autophagy and the epithelial-mesenchymal transition mediated by NICD\/ULK1 is involved in the formation of diabetic cataracts. Mol Med 28(1):116","journal-title":"Mol Med"},{"issue":"12","key":"11632_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.415","volume":"7","author":"M Gugnoni","year":"2016","unstructured":"Gugnoni M, Sancisi V, Manzotti G, Gandolfi G, Ciarrocchi A (2016) Autophagy and epithelial\u2013mesenchymal transition: an intricate interplay in cancer. Cell Death Dis 7(12):e2520\u2013e","journal-title":"Cell Death Dis"},{"key":"11632_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.757184","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Wang X, Ding J, Yang H, Xie Y (2021) Increased ATG5 expression predicts poor prognosis and promotes EMT in cervical carcinoma. Front Cell Dev Biol 9:757184","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"11632_CR97","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/path.5222","volume":"247","author":"AG Smith","year":"2019","unstructured":"Smith AG, Macleod KF (2019) Autophagy, cancer stem cells and drug resistance. J Pathol 247(5):708\u2013718","journal-title":"J Pathol"},{"issue":"5","key":"11632_CR98","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1158\/0008-5472.CAN-07-0562","volume":"68","author":"A Apel","year":"2008","unstructured":"Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A (2008) Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 68(5):1485\u20131494","journal-title":"Cancer Res"},{"key":"11632_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1431418","volume":"14","author":"M Haque","year":"2024","unstructured":"Haque M, Shyanti RK, Mishra MK (2024) Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer. Front Oncol 14:1431418","journal-title":"Front Oncol"},{"issue":"4","key":"11632_CR100","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/molecules26040885","volume":"26","author":"G Petrocelli","year":"2021","unstructured":"Petrocelli G, Farabegoli F, Valerii MC, Giovannini C, Sardo A, Spisni E (2021) Molecules present in plant essential oils for prevention and treatment of colorectal cancer (CRC). Molecules 26(4):885","journal-title":"Molecules"},{"key":"11632_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24213979","author":"M Fathy","year":"2019","unstructured":"Fathy M, Fawzy MA, Hintzsche H, Nikaido T, Dandekar T, Othman EM (2019) Eugenol exerts apoptotic effect and modulates the sensitivity of HeLa cells to cisplatin and radiation. Molecules. https:\/\/doi.org\/10.3390\/molecules24213979","journal-title":"Molecules"},{"issue":"2","key":"11632_CR102","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9 J (2008) TGFbeta in cancer. Cell 134(2):215\u201330","journal-title":"Cell"},{"key":"11632_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01384-8","volume":"20","author":"H Ji","year":"2020","unstructured":"Ji H, Liu G, Han J, Zhu F, Dong X, Li B (2020) C-phycocyanin inhibits epithelial-to-mesenchymal transition in Caski cells. Cancer Cell Int 20:292","journal-title":"Cancer Cell Int"},{"issue":"5","key":"11632_CR104","first-page":"2139","volume":"42","author":"V Aedo-Aguilera","year":"2019","unstructured":"Aedo-Aguilera V, Carrillo-Beltr\u00e1n D, Calaf GM, Mu\u00f1oz JP, Guerrero N, Osorio JC et al (2019) Curcumin decreases epithelial-mesenchymal transition by a Pirin-dependent mechanism in cervical cancer cells. Oncol Rep 42(5):2139\u20132148","journal-title":"Oncol Rep"},{"key":"11632_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1461894","volume":"15","author":"W Xie","year":"2024","unstructured":"Xie W, Xu Z (2024) (Nano)biotechnological approaches in the treatment of cervical cancer: integration of engineering and biology. Front Immunol 15:1461894","journal-title":"Front Immunol"},{"key":"11632_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010025","author":"M Cordani","year":"2019","unstructured":"Cordani M, Strippoli R, Somoza A (2019) Nanomaterials as inhibitors of epithelial mesenchymal transition in cancer treatment. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12010025","journal-title":"Cancers (Basel)"},{"key":"11632_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145774","volume":"794","author":"M Panji","year":"2021","unstructured":"Panji M, Behmard V, Zare Z, Malekpour M, Nejadbiglari H, Yavari S et al (2021) Suppressing effects of green tea extract and Epigallocatechin-3-gallate (EGCG) on TGF-\u03b2- induced epithelial-to-mesenchymal transition via ROS\/Smad signaling in human cervical cancer cells. Gene 794:145774","journal-title":"Gene"},{"key":"11632_CR108","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/nu14245273","volume":"14","author":"M Nadile","year":"2022","unstructured":"Nadile M, Retsidou MI, Gioti K, Beloukas A, Tsiani E (2022) Resveratrol against cervical cancer: evidence from in vitro and in vivo studies. Nutrients 14:24","journal-title":"Nutrients"},{"issue":"12","key":"11632_CR109","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3390\/ijms17122000","volume":"17","author":"K Cheng","year":"2016","unstructured":"Cheng K, Hao M (2016) Metformin inhibits TGF-\u03b21-induced epithelial-to-mesenchymal transition via PKM2 relative-mTOR\/p70s6k signaling pathway in cervical carcinoma cells. Int J Mol Sci 17(12):2000","journal-title":"Int J Mol Sci"},{"issue":"6","key":"11632_CR110","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1124\/mol.114.094037","volume":"86","author":"SC Chu","year":"2014","unstructured":"Chu SC, Yu CC, Hsu LS, Chen KS, Su MY, Chen PN (2014) Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells. Mol Pharmacol 86(6):609\u2013623","journal-title":"Mol Pharmacol"},{"key":"11632_CR111","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2147\/IJN.S234679","volume":"15","author":"Q Wang","year":"2020","unstructured":"Wang Q, Liu F, Wang L, Xie C, Wu P, Du S et al (2020) Enhanced and prolonged antitumor effect of salinomycin-loaded gelatinase-responsive nanoparticles via targeted drug delivery and inhibition of cervical cancer stem cells. Int J Nanomed 15:1283\u20131295","journal-title":"Int J Nanomed"},{"issue":"1","key":"11632_CR112","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/10717544.2021.1886378","volume":"28","author":"Q Wang","year":"2021","unstructured":"Wang Q, Yen YT, Xie C, Liu F, Liu Q, Wei J et al (2021) Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells. Drug Deliv 28(1):510\u20139","journal-title":"Drug Deliv"},{"issue":"9","key":"11632_CR113","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamaoncol.2024.2145","volume":"10","author":"M Birrer","year":"2024","unstructured":"Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP et al (2024) Bintrafusp alfa for recurrent or metastatic cervical cancer after platinum failure: a nonrandomized controlled trial. JAMA Oncol 10(9):1204\u201311","journal-title":"JAMA Oncol"},{"issue":"2","key":"11632_CR114","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ygyno.2013.05.008","volume":"130","author":"AV Tinker","year":"2013","unstructured":"Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS et al (2013) Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC clinical trials group (NCIC CTG IND 199). Gynecol Oncol 130(2):269\u201374","journal-title":"Gynecol Oncol"},{"issue":"22","key":"11632_CR115","doi-asserted-by":"publisher","first-page":"11168","DOI":"10.18632\/oncotarget.2584","volume":"5","author":"MM Hou","year":"2014","unstructured":"Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL et al (2014) Targeted PI3K\/AKT\/mTOR therapy for metastatic carcinomas of the cervix: a phase I clinical experience. Oncotarget 5(22):11168\u201379","journal-title":"Oncotarget"},{"issue":"8","key":"11632_CR116","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.humpath.2011.08.025","volume":"43","author":"Y Cheng","year":"2012","unstructured":"Cheng Y, Zhou Y, Jiang W, Yang X, Zhu J, Feng D (2012) Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma. Hum Pathol 43(8):1213\u201320","journal-title":"Hum Pathol"},{"key":"11632_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00022","volume":"7","author":"Y Tian","year":"2020","unstructured":"Tian Y, Qi P, Niu Q, Hu X (2020) Combined Snail and E-cadherin predicts overall survival of cervical carcinoma patients: comparison among various epithelial-mesenchymal transition proteins. Front Mol Biosci 7:22","journal-title":"Front Mol Biosci"},{"key":"11632_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-017-0450-6","volume":"17","author":"J Lin","year":"2017","unstructured":"Lin J, Lu J, Wang C, Xue X (2017) The prognostic values of the expression of Vimentin, TP53, and Podoplanin in patients with cervical cancer. Cancer Cell Int 17:80","journal-title":"Cancer Cell Int"},{"key":"11632_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111469","author":"L Greco","year":"2021","unstructured":"Greco L, Rubbino F, Morelli A, Gaiani F, Grizzi F, de\u2019Angelis GL et al (2021) Epithelial to mesenchymal transition: a challenging playground for translational research. Current models and focus on TWIST1 relevance and gastrointestinal cancers. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222111469","journal-title":"Int J Mol Sci"},{"key":"11632_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00605","volume":"8","author":"AF Teixeira","year":"2020","unstructured":"Teixeira AF, Ten Dijke P, Zhu HJ (2020) On-target anti-TGF-\u03b2 therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front Cell Dev Biol 8:605","journal-title":"Front Cell Dev Biol"},{"key":"11632_CR121","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.semcancer.2018.11.007","volume":"56","author":"B Das","year":"2019","unstructured":"Das B, Sarkar N, Bishayee A, Sinha D (2019) Dietary phytochemicals in the regulation of epithelial to mesenchymal transition and associated enzymes: a promising anticancer therapeutic approach. Semin Cancer Biol 56:196\u2013218","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"11632_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13355-7","volume":"24","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Xie C, Zhao R, Wang S, Xie Z, Pang Z et al (2024) Detecting epithelial-mesenchymal transition signaling molecules in cervical epithelial cells aids in the early diagnosis of cervical lesions. BMC Cancer 24(1):1582","journal-title":"BMC Cancer"},{"key":"11632_CR123","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-3-319-55947-6_11","volume":"994","author":"S Werner","year":"2017","unstructured":"Werner S, Stenzl A, Pantel K, Todenh\u00f6fer T (2017) Expression of epithelial mesenchymal transition and cancer stem cell markers in circulating tumor cells. Adv Exp Med Biol 994:205\u2013228","journal-title":"Adv Exp Med Biol"},{"key":"11632_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1277772","volume":"13","author":"A Jafari","year":"2023","unstructured":"Jafari A, Farahani M, Abdollahpour-Alitappeh M, Manzari-Tavakoli A, Yazdani M, Rezaei-Tavirani M (2023) Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical cancer stem cells. Front Oncol 13:1277772","journal-title":"Front Oncol"},{"key":"11632_CR125","first-page":"772","volume":"21","author":"M Khodayi","year":"2022","unstructured":"Khodayi M, Khalaj-Kondori M, Hoseinpour Feizi MA, Jabarpour Bonyadi M, Talebi M (2022) Plasma lncRNA profiling identified BC200 and NEAT1 lncRNAs as potential blood-based biomarkers for late-onset Alzheimer\u2019s disease. EXCLI J 21:772\u2013785","journal-title":"EXCLI J"},{"issue":"9","key":"11632_CR126","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s12033-023-00872-2","volume":"66","author":"N Riazi-Tabrizi","year":"2024","unstructured":"Riazi-Tabrizi N, Khalaj-Kondori M, Safaei S, Amini M, Hassanian H, Maghsoudi M et al (2024) NRF2 suppression enhances the susceptibility of pancreatic cancer cells, Miapaca-2 to paclitaxel. Mol Biotechnol 66(9):2441\u201354","journal-title":"Mol Biotechnol"},{"issue":"7","key":"11632_CR127","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S et al (2024) Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell 187(7):1617\u201335","journal-title":"Cell"},{"key":"11632_CR128","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-20301-6","volume-title":"Breast cancer metastasis and drug resistance: challenges and progress","author":"A Ahmad","year":"2019","unstructured":"Ahmad A (2019) Breast cancer metastasis and drug resistance: challenges and progress. Springer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11632-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11632-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11632-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:02:44Z","timestamp":1776333764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11632-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11632"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11632-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Assisted Technology. The authors acknowledge that no auxiliary tools were used in producing the article's content and that artificial intelligence technology was used only for minor grammatical editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Artificial Intelligence (AI)"}}],"article-number":"618"}}